Treatment-resistant hypertension affects millions of adults who cannot achieve target blood pressure despite multiple medications, creating elevated cardiovascular risk and limited therapeutic options. This condition represents a significant clinical challenge where conventional approaches reach their limits.
Lorundrostat demonstrates meaningful blood pressure reduction in patients with specific hormonal profiles characterized by suppressed renin activity and elevated aldosterone. The compound operates through selective inhibition of CYP11B2, the enzyme responsible for aldosterone synthesis. Clinical data shows both 50mg and 100mg daily doses significantly lowered systolic pressure compared to placebo across different patient cohorts in the Target-HTN trial.
The drug's selectivity advantage over CYP11B1 distinguishes it from earlier aldosterone synthase inhibitors like osilodrostat, which caused problematic cortisol suppression. This precision targeting potentially eliminates the adrenal insufficiency risks that plagued previous compounds in this class. Additional selective inhibitors including baxdrostat, dexfadrostat, and BI 690517 are advancing through development pipelines.
While these Phase 2 results appear encouraging, the findings require validation through larger Phase 3 studies before clinical adoption. The therapeutic approach represents a mechanistically distinct strategy for resistant hypertension, particularly relevant for patients with primary aldosteronism or aldosterone excess. However, questions remain about long-term safety, optimal patient selection criteria, and comparative effectiveness against established resistant hypertension treatments like renal denervation or spironolactone optimization.